Denali Therapeutics Inc. (DNLI): Depreciation & Amortization
$11.18M
Year ended 2025-12-31
$12.23M
Trailing 12 months to 2026-06-30
+2.5%
3-year compound annual growth
+5.6%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $11.18M | +43.5% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $7.79M | -53.4% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $16.73M | +61.1% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $10.38M | +20.8% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $8.59M | +0.7% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $8.53M | +6.8% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $7.99M | +7.8% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $7.42M | +140.6% | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | $3.08M | +109.8% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $1.47M | n/a | 2019-03-12, From 2016-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | 2025-12-31 | $11.18M | +43.5% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $8.58M | -3.1% |
| Amgen Inc (AMGN) | 2025-12-31 | $5.17B | -7.6% |
| Repligen Corp (RGEN) | 2025-12-31 | $78.75M | +13.0% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $1.38M | -16.0% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $97.36M | -11.4% |
| Biogen Inc. (BIIB) | 2025-12-31 | $779.90M | +15.8% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $699.0K | +19.1% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $1.39M | +11.5% |
Compare DNLI, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗